Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Ionis Pharmaceuticals $632.5 million convertible senior notes offering
We advised the purchasers on the Rule 144A convertible notes offering
Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering
Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering
Alignment Healthcare $489.6 million IPO
We advised the underwriters on the IPO and Nasdaq listing
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock
Charles River Laboratories International $1 billion senior notes offering
We advised Charles River Laboratories on the high-yield debt offering
Solid Biosciences $143.75 million follow-on equity offering
We advised the joint book-running managers on the stock offering
Connect Biopharma $219.9 million IPO
We advised the underwriters on the IPO and Nasdaq listing